02-06-2002



	Form PTO-1595 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002)  RE  1019 PAIENT	U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office
ŀ	Tab settings	Please record the attached original documents or copy thereof.
	Name of conveying party(ies):     LUDWIG INSTITUTE FOR CANCER     RESEARCH	2. Name and address of receiving party(ies)  Name: GILEAD SCIENCES, INC.  Internal Address: 333 Lakeside Drive Foster City, CA 94404
	Additional name(s) of conveying party(ies) attached? 🖳 Yes 🔀 No	r oster only, or v or ro
	3. Nature of conveyance:	
	Assignment	
	Security Agreement	
	Other	
	December 12, 2001 Execution Date:	Additional name(s) & address(es) attached? 📮 Yes 📳 No
ľ	4. Application number(s) or patent number(s):	
	If this document is being filed together with a new appli	cation, the execution date of the application is:
	A. Patent Application No.(s) 09/859,724	B. Patent No.(s)
	·	ached? Tyes Ki No JAN 28 2002
	5. Name and address of party to whom correspondence	6. Total number of applications and patents involved:
	concerning document should be mailed:	7. Total fee (37 CFR 3.41)\$ 40.00
	Barry J. Swanson Swanson & Bratschun, L.L.C.	   ☑ Enclosed
	1745 Shea Center Drive, Suite 330 Highlands Ranch, Colorado 80129	Authorized to be charged to deposit account
		8. Deposit account number:
02/06/2002 01 FC:581	DBYRNE 00000021 09859724 40.00 OP	(Attach duplicate copy of this page if paying by deposit account)
	DO NOT USE THIS SPACE	
	is a true copy of the original document.	information is true and correct and any attached copy  Demour (18,300)  Signature Date

Total number of pages including cover sheet, attachments, and documents:

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents & Trademarks, Box Assignments

Washington, D.C. 20231

**PATENT REEL: 012538 FRAME: 0530** 

## **ASSIGNMENT**

WHEREAS, the undersigned Ludwig Institute for Cancer Research ("Assignor") is the owner of the invention entitled Method for Treatment of Tumors Using Nucleic Acid Ligands to PDGF for which an application for United States Letters Patent was filed on May 17, 2001 as Application Serial No. 09/859,724, and PCT International Application No. PCT/US01/16078, and

WHEREAS, Gilead Sciences, Inc., a Delaware corporation ("Assignee") having a place of business at 333 Lakeside Drive, Foster City, California 94404, desires to acquire all right, title and interest in and to the above identified invention and application;

NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the above identified invention and applications, together with all corresponding foreign applications and patents which may be filed thereon, including the right to claim priority from the above identified United States application; and Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, renewal, extension and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the invention in all countries, this obligation to be binding upon Assignor (each and severally, if more than one) and upon Assignor's personal representative or other legal successor.

IN TESTIMONY WHEREOF, the undersigned Assignor has signed below.

Date:

Address:

S:\Client Folders\NeXstar\Nex90\Assignment3 between companies.doc

RECORDED: 01/28/2002

PATENT

LUDWIG INSTITUTE FOR CANCER RESEARCH

REEL: 012538 FRAME: 0531